
Irene A Abela

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5060875/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Alpha Variant Coronavirus Outbreak in a Nursing Home Despite High Vaccination Coverage: Molecular, Epidemiological, and Immunological Studies. Clinical Infectious Diseases, 2023, 77, 537-546.	5.8	5
2	Successful Induction of Specific Immunological Tolerance by Combined Kidney and Hematopoietic Stem Cell Transplantation in HLA-Identical Siblings. Frontiers in Immunology, 2022, 13, 796456.	4.8	2
3	Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 214.e1-214.e11.	1.2	32
4	Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS). HIV Medicine, 2022, 23, 417-425.	2.2	6
5	Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. Clinical Infectious Diseases, 2022, 75, e585-e593.	5.8	26
6	Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. Journal of Clinical Investigation, 2022, 132, .	8.2	26
7	Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease. PLoS Biology, 2022, 20, e3001709.	5.6	29
8	SARS-CoV-2 variants reveal features critical for replication in primary human cells. PLoS Biology, 2021, 19, e3001006.	5.6	46
9	Subacute cerebellar ataxia following respiratory symptoms of COVID-19: a case report. BMC Infectious Diseases, 2021, 21, 298.	2.9	19
10	Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools. BMJ, The, 2021, 372, n616.	6.0	68
11	A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®. Trials, 2021, 22, 724.	1.6	9
12	Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity. Nature Communications, 2021, 12, 6703.	12.8	36
13	Evolution of SARS-CoV-2 seroprevalence and clusters in school children from June 2020 to April 2021: prospective cohort study Ciao Corona. Swiss Medical Weekly, 2021, 151, w30092.	1.6	25
14	Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. Clinical Infectious Diseases, 2020, 70, 297-303.	5.8	10
15	Large and Small Cerebral Vessel Involvement in Severe COVID-19. Stroke, 2020, 51, 3719-3722.	2.0	89
16	Seroprevalence and immunity of SARS-CoV-2 infection in children and adolescents in schools in Switzerland: design for a longitudinal, school-based prospective cohort study. International Journal of Public Health, 2020, 65, 1549-1557.	2.3	34
17	Does respiratory co-infection facilitate dispersal of SARS-CoV-2? investigation of a super-spreading event in an open-space office. Antimicrobial Resistance and Infection Control, 2020, 9, 191.	4.1	19
18	Correlates of broadly neutralizing antibody development. Current Opinion in HIV and AIDS, 2019, 14, 279-285	3.8	9

IRENE A ABELA

#	Article	IF	CITATIONS
19	A cluster of scedosporiosis in lung transplant candidates and recipients: The Zurich experience and review of the literature. Transplant Infectious Disease, 2018, 20, e12792.	1.7	11
20	Cell-Cell Transmission Enables HIV-1 to Evade Inhibition by Potent CD4bs Directed Antibodies. PLoS Pathogens, 2012, 8, e1002634.	4.7	189
21	Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances. Current Pharmaceutical Design, 2010, 16, 3754-3766.	1.9	8